findmyKOL
Clinical trialNCT03702725CompletedPhase 1Interventional

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

SponsorAlliance Foundation Trials, LLC.Enrollment14Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Loyola University Medical Center

    Maywood, Illinois, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina, United States

  • the Ohio State University Wexner Medical Center/james Cancer Hospital

    Columbus, Ohio, United States

  • Rhode Island Hospital

    Providence, Rhode Island, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dexamethasone →Ibrutinib →Lenalidomide →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
29 Aug 2019
Primary completion
27 Sept 2024
Completion
4 Oct 2024
Last update posted
6 Jan 2026
Registered enrollment
14
Registry id
NCT03702725
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.